Relmada Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for RLMD, updated each market day.
RLMD AI Sentiment
AI sees no strong directional signal for Relmada Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Relmada Therapeutics, Inc. Common Stock
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Sector
Exchange
Market Cap
$798,199,453
Cap Tier
Employees
17
Headquarters
CORAL GABLES, FL
Listed Since
March 3, 2014
Website
RLMD Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RLMD Volatility
Relmada Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
